The Journal of Immunology, Vol 155, Issue 10 4955-4962, Copyright © 1995 by American Association of Immunologists

ARTICLES

Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b

MW Ollert, K David, R Bredehorst and CW Vogel
Department of Biochemistry and Molecular Biology, University of Hamburg, Germany.

The restriction of alternative complement pathway activation in fluid phase or on nonactivator surfaces has been described as the major physiologic function of the complement regulatory protein factor H. In this study, we provide evidence that factor H is also a restriction factor of classical pathway activation on the surface of nucleated cells. We found that C3b was rapidly converted to inactivated C3b (iC3b) on human SK-MEL-93-2 melanoma cells after classical pathway activation with the murine monoclonal IgG3 Ab R24 directed against the disialoganglioside surface Ag GD3. The SK-MEL-93-2 cells are nonactivators of the alternative pathway and express neither CR1 (CD35) nor the C3b-cleaving protease p65. The cells are further characterized by the expression of only moderate amounts of DAF (CD55) and approximately 5 x 10(3) MCP (CD46) molecules/cell. FACS analysis and direct quantitation using [125I]factor H revealed high level binding of factor H to the melanoma cells (5.6 x 10(6) molecules/cell) during classical pathway activation. The binding of factor H could be inhibited under conditions that inactivate the classical complement pathway (EGTA and heat treatment), but not by factor B depletion of the serum, demonstrating that classical pathway activation was responsible for factor H binding. Treatment of factor B-depleted serum with neutralizing concentrations of polyclonal anti-factor H resulted in the prolonged presence of intact C3b on the cells and a significantly reduced generation of iC3b. The increased amount of C3b on these cells correlated with a 2.65-fold greater rate of cell death. In contrast, the increase in cell death effected by neutralizing concentrations of anti-CD46 or anti-CD55 Ab was only 0.13- or 0.35-fold, respectively. In addition, the supplementation of serum with purified factor H decreased the extent of lysis of the cells. Collectively, these data provide experimental evidence that factor H, through its cofactor activity for C3b degradation, is involved in the restriction of the classical pathway of complement on the surface of nucleated cells, a function that to date has been exclusively attributed to the membrane regulatory proteins CD35 and CD46.

This article has been cited by other articles:

				D. Ajona, Y.-F. Hsu, L. Corrales, L. M. Montuenga, and R. Pio Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth J. Immunol., May 1, 2007; 178(9): 5991 - 5998. [Abstract] [Full Text] [PDF]

				J. J. Alexander, Y. Wang, A. Chang, A. Jacob, A. W.M. Minto, M. Karmegam, M. Haas, and R. J. Quigg Mouse Podocyte Complement Factor H: The Functional Analog to Human Complement Receptor 1 J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1157 - 1166. [Abstract] [Full Text] [PDF]

				J. J. Alexander, O.G.B. Aneziokoro, A. Chang, B. K. Hack, A. Markaryan, A. Jacob, R. Luo, M. Thirman, M. Haas, and R. J. Quigg Distinct and Separable Roles of the Complement System in Factor H-Deficient Bone Marrow Chimeric Mice with Immune Complex Disease J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1354 - 1361. [Abstract] [Full Text] [PDF]

				D. Ajona, Z. Castano, M. Garayoa, E. Zudaire, M. J. Pajares, A. Martinez, F. Cuttitta, L. M. Montuenga, and R. Pio Expression of Complement Factor H by Lung Cancer Cells: Effects on the Activation of the Alternative Pathway of Complement Cancer Res., September 1, 2004; 64(17): 6310 - 6318. [Abstract] [Full Text] [PDF]

				M. L. Barilla-LaBarca, M. K. Liszewski, J. D. Lambris, D. Hourcade, and J. P. Atkinson Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells J. Immunol., June 15, 2002; 168(12): 6298 - 6304. [Abstract] [Full Text] [PDF]

				S. Junnikkala, T. S. Jokiranta, M. A. Friese, H. Jarva, P. F. Zipfel, and S. Meri Exceptional Resistance of Human H2 Glioblastoma Cells to Complement-Mediated Killing by Expression and Utilization of Factor H and Factor H-Like Protein 1 J. Immunol., June 1, 2000; 164(11): 6075 - 6081. [Abstract] [Full Text] [PDF]

				S. Honda, F. Itoh, M. Yoshimoto, S. Ohno, Y. Hinoda, and K. Imai Association Between Complement Regulatory Protein Factor H and AM34 Antigen, Detected in Senile Plaques J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2000; 55(5): 265M - 269. [Abstract] [Full Text]

				M. J. Corey, R. J. Kinders, C. M. Poduje, C. L. Bruce, H. Rowley, L. G. Brown, G. M. Hass, and R. L. Vessella Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis J. Biol. Chem., April 21, 2000; 275(17): 12917 - 12925. [Abstract] [Full Text] [PDF]

				E. Johnsson, K. Berggard, H. Kotarsky, J. Hellwage, P. F. Zipfel, U. Sjobring, and G. Lindahl Role of the Hypervariable Region in Streptococcal M Proteins: Binding of a Human Complement Inhibitor J. Immunol., November 1, 1998; 161(9): 4894 - 4901. [Abstract] [Full Text] [PDF]

				W.-X. Shi, R. Chammas, N. M. Varki, L. Powell, and A. Varki Sialic Acid 9-O-Acetylation on Murine Erythroleukemia Cells Affects Complement Activation, Binding to I-type Lectins, and Tissue Homing J. Biol. Chem., December 6, 1996; 271(49): 31526 - 31532. [Abstract] [Full Text] [PDF]